Prashant Singh Rawat

MicroTransponder Completes $73M Series E Financing

Retrieved on: 
Wednesday, September 21, 2022
U.S. Venture Partners, VNS, FDA, Vagus nerve stimulation, Organization, Survivor, Intellectual property, COO, Stroke, Therapy, CEO, Technology, Research, Rehabilitation, Boston Scientific, Prashant Singh Rawat, Patent, Pharmaceutical industry, Medical device, Rawat

AUSTIN, Texas, Sept. 21, 2022 /PRNewswire/ -- MicroTransponder, Inc. positions for continued strategic growth, having finalized its oversubscribed $73 million Series E funding round and named Prashant Rawat chief operating officer (COO). The funding supports the market development and commercialization of MicroTransponder's FDA-approved Vivistim® Paired VNS™ System, a first-of-its-kind breakthrough technology that uses vagus nerve stimulation (VNS) during rehabilitation therapy to improve upper limb function for stroke survivors.

Key Points: 
  • AUSTIN, Texas, Sept. 21, 2022 /PRNewswire/ -- MicroTransponder, Inc. positions for continued strategic growth, having finalized its oversubscribed $73 million Series E funding round and named Prashant Rawat chief operating officer (COO).
  • The company's Series E was led by US Venture Partners , a multi-stage investment firm.
  • For more information about MicroTransponder and the first FDA-approved use of vagus nerve stimulation for stroke rehabilitation, visit Vivistim.com.
  • MicroTransponder, Inc. is a privately held, global medical device company based in Austin, Texas, committed to developing research-based neuroscience solutions.